January 2023, GNS announced a rebrand as Aitia to focus on AI-enabled drug drug discovery. CEO Colin Hill told BioCentury the company considered the shift five years ago, seeing appetite from investors and pharma partners. “Aitia’s decision to move into drug discovery after more than 20 years as a technology partner is a bet on its causal AI’s capacity to extract value from the recent boom in multi-omic patient data. The Massachusetts-based company formerly known as GNS Healthcare Inc. is keeping its focus on preclinical development, with plans to partner programs before IND.”
Read BioCentury covering story on GNS becoming Aitia here.